From the Journals
Selective JAK Inhibition in RA vs PV
-
By
February 13, 2026
-
3 min
-
1
Patient diagnosed with RA and PV at age
-
2
Tofacitinib was initiated for RA treatment.
-
3
Minimal effect on PV, demonstrated hematologic stability.
-
4
RA remission achieved within 3 months.
-
5
Treatment responses included normalization of inflammatory markers.
-
6
Hydroxyurea was continued with adjusted dosing.
-
7
No adverse events or cytopenias reported after 12 months.
-
Bogojevic et al. reported a case of a 61-year-old woman with seropositive rheumatoid arthritis (RA) and JAK2 V617F-positive polycythemia vera (PV) where the Janus kinase (JAK) inhibitor tofacitinib was used. While achieving effective control of RA symptoms, tofacitinib showed minimal effects on the hematologic abnormalities associated with PV. This highlights the differential impact of JAK inhibitors, which predominantly target JAK1 and JAK3, but not JAK2, emphasizing the need for targeted therapies in patients with both autoimmune disorders and myeloproliferative diseases.
-
1
Patient diagnosed with RA and PV at age
-
2
Tofacitinib was initiated for RA treatment.
-
3
Minimal effect on PV, demonstrated hematologic stability.
-
4
RA remission achieved within 3 months.
-
5
Treatment responses included normalization of inflammatory markers.
-
6
Hydroxyurea was continued with adjusted dosing.
-
7
No adverse events or cytopenias reported after 12 months.
Listen Tab content
